Trial · NCT00503113
Results by group48
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 48
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Absolute Change From Baseline in Actual Glomerular Filtration Rate (GFR) (Using Abbreviated Modification of Diet in Renal Disease [MDRD] Formula) | Ibandronate 3 mg Injection | Baseline | 72.5 | Standard Deviation 18.25 | mL/min |
| Absolute Change From Baseline in Actual Glomerular Filtration Rate (GFR) (Using Abbreviated Modification of Diet in Renal Disease [MDRD] Formula) | Ibandronate 3 mg Infusion | Baseline | 71.5 | Standard Deviation 18.07 | mL/min |
| Absolute Change From Baseline in Actual Glomerular Filtration Rate (GFR) (Using Abbreviated Modification of Diet in Renal Disease [MDRD] Formula) | Alendronate 70 mg Oral | Baseline | 70.5 | Standard Deviation 16.67 | mL/min |
| Absolute Change From Baseline in Actual Glomerular Filtration Rate (GFR) (Using Abbreviated Modification of Diet in Renal Disease [MDRD] Formula) | Ibandronate 3 mg Injection | Change from baseline at 9 months (n=233,232,225) | -1.3 | Standard Deviation 7.14 | mL/min |
| Absolute Change From Baseline in Actual Glomerular Filtration Rate (GFR) (Using Abbreviated Modification of Diet in Renal Disease [MDRD] Formula) | Ibandronate 3 mg Infusion | Change from baseline at 9 months (n=233,232,225) | -0.5 | Standard Deviation 7.86 | mL/min |
| Absolute Change From Baseline in Actual Glomerular Filtration Rate (GFR) (Using Abbreviated Modification of Diet in Renal Disease [MDRD] Formula) | Alendronate 70 mg Oral | Change from baseline at 9 months (n=233,232,225) | -1.6 | Standard Deviation 5.89 | mL/min |
| Absolute Change From Baseline in Actual GFR (Using Cockcroft-Gault [CG] Formula) | Ibandronate 3 mg Injection | Baseline | 65.0 | Standard Deviation 19.37 | mL/min |
| Absolute Change From Baseline in Actual GFR (Using Cockcroft-Gault [CG] Formula) | Ibandronate 3 mg Infusion | Baseline | 62.9 | Standard Deviation 18.22 | mL/min |
| Absolute Change From Baseline in Actual GFR (Using Cockcroft-Gault [CG] Formula) | Alendronate 70 mg Oral | Baseline | 62.0 | Standard Deviation 16.67 | mL/min |
| Absolute Change From Baseline in Actual GFR (Using Cockcroft-Gault [CG] Formula) | Ibandronate 3 mg Injection | Change from Baseline at 9 months (N=233,232,225) | -1.6 | Standard Deviation 5.89 | mL/min |
| Absolute Change From Baseline in Actual GFR (Using Cockcroft-Gault [CG] Formula) | Ibandronate 3 mg Infusion | Change from Baseline at 9 months (N=233,232,225) | -1.0 | Standard Deviation 6.44 | mL/min |
| Absolute Change From Baseline in Actual GFR (Using Cockcroft-Gault [CG] Formula) | Alendronate 70 mg Oral | Change from Baseline at 9 months (N=233,232,225) | -1.9 | Standard Deviation 4.84 | mL/min |
| Relative Change From Baseline in Actual GFR (Using Abbreviated MDRD Formula) | Ibandronate 3 mg Injection | Baseline | 72.5 | Standard Deviation 18.25 | mL/min |
| Relative Change From Baseline in Actual GFR (Using Abbreviated MDRD Formula) | Ibandronate 3 mg Infusion | Baseline | 71.5 | Standard Deviation 18.07 | mL/min |
| Relative Change From Baseline in Actual GFR (Using Abbreviated MDRD Formula) | Alendronate 70 mg Oral | Baseline | 70.5 | Standard Deviation 16.67 | mL/min |
| Relative Change From Baseline in Actual GFR (Using Abbreviated MDRD Formula) | Ibandronate 3 mg Injection | Relative Change at 9 month (n= 233, 232, 225) | -1.4 | Standard Deviation 10.01 | mL/min |
| Relative Change From Baseline in Actual GFR (Using Abbreviated MDRD Formula) | Ibandronate 3 mg Infusion | Relative Change at 9 month (n= 233, 232, 225) | -0.2 | Standard Deviation 10.73 | mL/min |
| Relative Change From Baseline in Actual GFR (Using Abbreviated MDRD Formula) | Alendronate 70 mg Oral | Relative Change at 9 month (n= 233, 232, 225) | -2.1 | Standard Deviation 8.64 | mL/min |
| Relative Change From Baseline in Actual GFR (Using CG Formula) | Ibandronate 3 mg Injection | Baseline | 65.0 | Standard Deviation 19.37 | mL/min |
| Relative Change From Baseline in Actual GFR (Using CG Formula) | Ibandronate 3 mg Infusion | Baseline | 62.9 | Standard Deviation 18.22 | mL/min |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00503113/results